luminescent proximity homogeneous assay alpha screening (Biacore)
Structured Review
Luminescent Proximity Homogeneous Assay Alpha Screening, supplied by Biacore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alpha+screen/alpha+assay+homogeneous+luminescent+proximity+screening/us12624077-144-38-34
Average 86 stars, based on 1 article reviews
Images
Related Articles
Binding Assay:Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as Activity Assay:Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as FACS:Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as Enzyme-linked Immunosorbent Assay:Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as Amplification:Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as SPR Assay:Article Title: Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB Article Snippet: .. Binding Activity to the Fcγ Receptor The binding activity of an FcγR-binding domain, which is included in an antigen-binding molecule of the present invention, to any of the human Fcγ receptors, FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa, and/or FcγRIIIb, can be confirmed by the above-described FACS and ELISA format, as well as |
![a Mechanism of action of conventional aEGFRvIII CAR T cell monotherapy in GBM. b Proposed aEGFRvIII-SGRP CAR T cell combination therapy whereby SGRP-mediated <t>CD47</t> blockade induces phagocytic modulation of GAMs in the context of EGFRvIII-heterogenous GBM and its immunosuppressive iTME. c Outline of the SGRP engineering strategy, including specific AA substitutions to the endogenous human SIRPγ-V1 sequence and addition of an N-terminal IL-2 signal sequence (IL2sig) leading to constitutive SGRP secretion. d Polycistronic lentiviral constructs encoding mCherry (mC)-labeled aCD19 CAR or aEGFRvIII CAR under the control of EF1A promoter ± SGRP secretion. e Workflow of CAR T cell production applied throughout the study. a – e Created in BioRender. Hutter, G. (2022) BioRender.com/u48r093. Representative plots of CAR:target protein binding by aCD19 CAR T cells ( f ) or aEGFRvIII CAR T cells ( g ) to CAR-bound <t>biotinylated</t> (bt)-CD19 (top plots) or bt-EGFRvIII (bottom plots); n = 2 healthy donors (HDs) assessed per CAR. h TATA-box binding protein (TBP)-normalized expression of mCherry and SGRP detected by real-time quantitative PCR (RT-qPCR) in aEGFRvIII CAR or aEGFRvIII-SGRP CAR T cells, showing mCherry expression in CARs transduced with either construct and SGRP expression specifically in aEGFRvIII-SGRP CARs; n = 4 HDs. Data are presented as scatter plots with mean values ± SD. Statistical differences were assessed by two-sided unpaired t tests with Welch’s correction. i Differentially secreted proteins in aEGFRvIII-SGRP CAR- vs aEGFRvIII CAR-conditioned media, highlighting the presence of SGRP exclusively in aEGFRvIII-SGRP CAR; n = 2 HDs. Mean SGRP expression: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$-\log 10{{{\rm{qValue}}}}/\log 2{{{\rm{foldchange}}}}=8.60/6.65$$\end{document} − log 10 qValue / log 2 foldchange = 8.60 / 6.65 . Source data are provided as a Source Data file. Source data for ( i ) are provided as Supplementary Data .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0474/pmc11550474/pmc11550474__41467_2024_54129_Fig1_HTML.jpg)